Alkermes (ALKS) Total Liabilities (2011 - 2026)
Alkermes' (ALKS) quarterly Total Liabilities came in at $2.5 billion in Q1 2026, up 339.44% year-on-year from $570.4 million in Q1 2025, and up 275.4% on a QoQ basis from $667.7 million in Q4 2025.
Alkermes (ALKS) Total Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Total Liabilities data on file, last reported at $2.5 billion in Q1 2026.
- On a quarterly basis, Total Liabilities rose 339.44% year-over-year to $2.5 billion in Q1 2026; TTM through Mar 2026 was $2.5 billion, a 339.44% increase from a year earlier, with the FY2025 full-year figure at $667.7 million, up 13.06% from the prior year.
- Total Liabilities for Q1 2026 stood at $2.5 billion, up from $667.7 million in the prior quarter.
- Over the last five years, Total Liabilities for ALKS reached as high as $2.5 billion in Q1 2026 and fell as low as $570.4 million in Q1 2025.
- Historically, Total Liabilities has averaged $911.3 million across 5 years, with a median of $899.0 million in 2022.
- Across the five-year window, Total Liabilities tumbled 36.74% in 2024 and surged 339.44% in 2026, its largest moves.
- Year by year, Total Liabilities stood at $920.2 million in 2022, then gained by 1.45% to $933.5 million in 2023, then tumbled by 36.74% to $590.6 million in 2024, then climbed by 13.06% to $667.7 million in 2025, then soared by 275.4% to $2.5 billion in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $2.5 billion in Q1 2026, $667.7 million in Q4 2025, and $596.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.48 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 31.81 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.92 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 51.53 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 813.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 22.18 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.50 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.72 Bn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 2.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.51 Bn |
| Dec 31, 2025 | 667.70 Mn |
| Sep 30, 2025 | 596.08 Mn |
| Jun 30, 2025 | 628.23 Mn |
| Mar 31, 2025 | 570.39 Mn |
| Dec 31, 2024 | 590.59 Mn |
| Sep 30, 2024 | 863.19 Mn |
| Jun 30, 2024 | 922.84 Mn |
| Mar 31, 2024 | 869.13 Mn |
| Dec 31, 2023 | 933.54 Mn |
| Sep 30, 2023 | 923.65 Mn |
| Jun 30, 2023 | 906.75 Mn |
| Mar 31, 2023 | 917.15 Mn |
| Dec 31, 2022 | 920.23 Mn |
| Sep 30, 2022 | 899.05 Mn |
| Jun 30, 2022 | 875.09 Mn |
| Mar 31, 2022 | 902.46 Mn |
| Dec 31, 2021 | 911.90 Mn |
| Sep 30, 2021 | 899.26 Mn |
| Jun 30, 2021 | 839.67 Mn |